Madrigal Pharmaceuticals
MDGL
100 hedge funds and large institutions have $739M invested in Madrigal Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 19 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
57% more capital invested
Capital invested by funds: $471M → $739M (+$268M)
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
10% more funds holding
Funds holding: 91 → 100 (+9)
7.95% more ownership
Funds ownership: 36.5% → 44.46% (+8%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$123M |
| 2 |
State Street
Boston,
Massachusetts
|
+$48.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$31.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$61.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.5M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$10.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.89M |
MDGL Hedge Fund Activity: Q1 2018 in Review
100 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2018, worth a combined $739M — up 57% from $471M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MDGL positions and 19 closed out — a net gain of 10 holders — while 38 added to existing stakes and 24 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $123M. The largest seller was Fidelity Investments, cutting an estimated $61.3M.
- 100 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2018, up from 91 in Q4 2017.
- Funds reported $739M of Madrigal Pharmaceuticals stock for Q1 2018, up 57% quarter-over-quarter.
- 29 funds opened new Madrigal Pharmaceuticals positions in Q1 2018 and 19 closed out, a net change of +10 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2018 was Capital Research Global Investors, an estimated $123M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2018 was Fidelity Investments, an estimated $61.3M sold.
Based on aggregated 13F filings for Q1 2018.